In late July, Indonesia’s government announced GR 28 which is similar to the Indonesian Health Omnibus Law, but with more detailed explanations. This new regulation covers a number of topics. First, it states that the National Health Information System can use data from robotic products or AI products. This is a change since earlier regulations did not include robotics or AI products to be in their system. Second, it outlines that healthcare technology, or more specifically electronic receipts, can be utilized for health issues including diagnosis and treatment as long as they are logged into the National Health Information System. Third, telemedicine can be utilized via an app in hospitals, clinics, pharmacies, etc. Fourth, it provides more guidance on the value of health technology being used for treatment, diagnosis, and prevention. Finally, it further defines the requirements for biobanking. Permits are required for biobank operators, but all specimens must be kept in Indonesia.
Also included in GR 28, are new details on other healthcare topics. For example, it sets up a medical ethical panel (to be comprised of doctors and healthcare legal specialists) to bolster the Indonesian Health Council to upgrade the technical skills and overall quality of healthcare specialists. In addition, this new regulation provides more details on the responsibilities of Indonesian hospitals, improves hospital management requirements, and divides educational hospitals into main and satellite institutions with each having its own specific requirements and functions.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.